The short version
Semaglutide is a 31-amino-acid analogue of human GLP-1 that activates one receptor. It has been approved since 2017 (Ozempic, type 2 diabetes), 2019 (Rybelsus, oral) and 2021 (Wegovy, weight management), with completed cardiovascular, kidney and heart-failure outcome trials. Retatrutide is a 39-amino-acid GIP-based peptide that activates three receptors — GIP, GLP-1 and glucagon — and is still in phase 3, unapproved anywhere as of September 2026. In separate trials, semaglutide 2.4 mg produced −14.9% body weight at 68 weeks (STEP 1) and retatrutide 12 mg produced −24.2% at 48 weeks (phase 2). They have never been compared directly.
Two different molecules, not two versions of one
Set the structures side by side and they share the design toolkit but not the blueprint. Semaglutide starts from GLP-1: it keeps 29 of the hormone's 31 residues, puts Aib at position 8 to block DPP-4, swaps Lys34 for Arg, and attaches a C18 fatty diacid to Lys26 so the peptide rides on albumin for about a week. Retatrutide starts from the other incretin, GIP, adds an exendin-4 tail, uses three non-canonical residues (Aib2, α-methyl-leucine13, Aib20), tunes the mid-chain for glucagon receptor activity, and attaches a C20 fatty diacid to Lys17. Its N-terminal tyrosine (GIP) versus semaglutide's histidine (GLP-1) is the giveaway that these are different hormone families.
| Feature | Semaglutide | Retatrutide |
|---|---|---|
| Parent hormone | GLP-1 (human) | GIP (human) + exendin-4 tail |
| Length | 31 aa | 39 aa |
| Non-canonical residues | Aib8 | Aib2, αMeLeu13, Aib20 |
| Acylation | Lys26 · C18 diacid-γGlu-2×OEG | Lys17 · C20 diacid-γGlu-OEG |
| Formula / mass | C187H291N45O59 / ≈ 4,114 Da | C221H342N46O68 / ≈ 4,731 Da |
| Receptors | GLP-1R | GIPR + GLP-1R + GCGR |
| Half-life | ≈ 7 days | ≈ 6 days |
| Oral form | Yes (Rybelsus, with SNAC) | No |
| Status (Sept 2026) | Approved worldwide | Investigational, phase 3 |
One receptor versus three
Everything semaglutide does runs through the GLP-1 receptor: amplified glucose-dependent insulin secretion, glucagon suppression, slower gastric emptying and reduced appetite. Retatrutide keeps that pathway and adds two more. GIP receptor activation contributes insulin secretion, adipose-tissue signalling and, apparently, a softening of GLP-1-related nausea; it is the mechanism tirzepatide added. Glucagon receptor activation raises energy expenditure and drives fat oxidation in the liver — the new element, and the likely reason retatrutide's weight loss and liver-fat reductions exceed the dual agonists. Glucagon also raises glucose and heart rate, so the three activities were deliberately balanced with the incretin components dominant.
Half-life and dosing
Both are once-weekly injections. Semaglutide's half-life is about 7 days (145–165 hours); retatrutide's about 6 days. Semaglutide for weight management escalates over 16 weeks to 2.4 mg; Ozempic for diabetes tops out at 2 mg. Retatrutide's trials started at 2 mg or 4 mg and escalated to 4, 8, 9 or 12 mg — the milligram numbers are not comparable across molecules, since potency per milligram differs. Semaglutide alone has an oral formulation, Rybelsus, which relies on the SNAC absorption enhancer and strict empty-stomach dosing.
Weight-loss data, side by side (different trials)
STEP 1 (Wilding et al., NEJM 2021; 1,961 adults with overweight or obesity, 68 weeks): semaglutide 2.4 mg −14.9% versus −2.4% placebo, with 50.5% of participants losing at least 15%. Retatrutide phase 2 (Jastreboff et al., NEJM 2023; 338 adults, 48 weeks): 12 mg −24.2% versus −2.1% placebo, with 83% losing at least 15%, and weight still falling at 48 weeks. The difference is large, but the trials differ in size, duration and era, and phase 2 results routinely shrink in phase 3. In type 2 diabetes, retatrutide's phase 3 TRANSCEND-T2D-1 reported −15.3% at 40 weeks on 12 mg; semaglutide's diabetes trials (SUSTAIN) reported weight changes of roughly 4–6 kg at 1 mg.
| Trial | Drug / dose | Population | Duration | Weight change (placebo) |
|---|---|---|---|---|
| STEP 1 (2021) | Semaglutide 2.4 mg | Obesity, no diabetes | 68 weeks | −14.9% (−2.4%) |
| Phase 2 obesity (2023) | Retatrutide 12 mg | Obesity, no diabetes | 48 weeks | −24.2% (−2.1%) |
| SURMOUNT-5 (2025) | Semaglutide 2.4 mg vs tirzepatide | Obesity, no diabetes | 72 weeks | −13.7% (tirzepatide −20.2%) |
| TRANSCEND-T2D-1 (2026) | Retatrutide 12 mg | Type 2 diabetes | 40 weeks | −15.3% (−2.6%) |
Where semaglutide's evidence has no counterpart yet
Weight is one endpoint. Semaglutide has completed the outcome trials that define a drug's place: SELECT (20% relative reduction in major cardiovascular events in obesity without diabetes), SUSTAIN-6 (cardiovascular events in diabetes), FLOW (24% reduction in kidney-disease progression), STEP-HFpEF (heart failure symptoms), plus nine years of post-marketing safety data across tens of millions of prescriptions. Retatrutide's cardiovascular outcomes trial, TRIUMPH-Outcomes, is running and had not reported as of September 2026. For a reader deciding what the phase 2 percentage means, this asymmetry is the most important line in the comparison.
Side effects: the same class plus two signals
Both produce dose-related, mostly mild-to-moderate gastrointestinal events that cluster during escalation — nausea, diarrhoea, vomiting, constipation — and both carry the incretin-class cautions (pancreatitis, gallbladder disease, the rodent thyroid C-cell warning, hypoglycaemia with insulin or sulfonylureas). Retatrutide's trials added a dose-dependent heart-rate increase that peaked around 24 weeks and skin sensitivity (dysesthesia) at higher doses, both plausibly linked to glucagon receptor activity. Semaglutide's profile is documented in a label; retatrutide's is documented in trial reports totalling a few thousand participants.
Approval, availability and what “vs Ozempic” really asks
Ozempic and Wegovy are approved, manufactured under pharmaceutical GMP, and dispensed by prescription. Retatrutide exists only in trials and, since August 2026, in Lilly's pre-approval expanded-access programme for a defined patient group; Lilly plans a US filing in early 2027. Anything sold online under the retatrutide name is unlicensed material of unverified content. So the honest answer to “is retatrutide better than Ozempic?” is: its phase 2 weight loss was larger, its long-term and outcomes evidence does not exist yet, and there is currently no legitimate way to be prescribed it outside those two channels. This guide is educational, not medical advice, and choosing between approved medicines is a prescriber's decision.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Li et al. (2024) — Structural basis of retatrutide triple-receptor agonism
Structural receptor research; biological plausibility is separate from proven clinical benefit.
Relevant sections: Two different molecules, not two versions of one · One receptor versus three
- Jastreboff et al. (2023) — Retatrutide for obesity, phase 2 trial
Phase 2 obesity trial: studied regimens, weight and adverse events. Trial doses are not instructions for personal use.
Relevant sections: Weight-loss data, side by side (different trials) · Side effects: the same class plus two signals
- Wilding et al. (2021) — STEP 1: once-weekly semaglutide in adults with obesity
Randomized obesity trial with defined participants and endpoints; cross-trial percentages are not a head-to-head comparison.
Relevant sections: Weight-loss data, side by side (different trials)
- Lincoff et al. (2023) — Semaglutide and cardiovascular outcomes in obesity
SELECT trial in adults with established cardiovascular disease; outcome evidence is specific to that population.
Relevant sections: Where semaglutide's evidence has no counterpart yet
FAQ
What is the difference between retatrutide and semaglutide?+
Semaglutide is a GLP-1 analogue acting on one receptor; retatrutide is a GIP-based peptide acting on the GIP, GLP-1 and glucagon receptors. Semaglutide is approved (Ozempic, Wegovy, Rybelsus); retatrutide is investigational.
Is retatrutide better than Ozempic or Wegovy for weight loss?+
No head-to-head trial exists. Retatrutide's phase 2 reached −24.2% at 48 weeks; semaglutide 2.4 mg reached −14.9% at 68 weeks in STEP 1. Different trials, and retatrutide has no long-term or outcomes data yet.
Is retatrutide a GLP-1 like semaglutide?+
It activates the GLP-1 receptor, but its sequence is GIP-based and it also activates the GIP and glucagon receptors. Semaglutide is a true GLP-1 analogue.
Which has the longer half-life?+
Semaglutide, at about 7 days versus retatrutide's roughly 6. Both are dosed once weekly.
Can you get retatrutide instead of Ozempic?+
Not as a prescription. As of September 2026 retatrutide is unapproved and available only in clinical trials and Lilly's expanded-access programme.
Related peptide profiles
More guides
- Retatrutide vs Tirzepatide: Triple vs Dual Agonist — Structure, Half-Life, Trial Data
- Semaglutide vs Tirzepatide: Structure, Receptors, Half-Life and the SURMOUNT-5 Head-to-Head
- Retatrutide Side Effects: What the Clinical Trials Actually Reported
- GLP-1 and Incretin Peptide Half-Lives Compared: From 2 Minutes to 8 Days